Table 1. In vivo efficacy of SC16LD6.5 and TIC frequency in SCLC and LCNEC PDX.

%TGI, percent tumor growth inhibition; Q4D×3, once every 4 days for a total of three doses; N.D., not determined; SD, single dose. SOC for SCLC: cisplatin (5 mg/kg) SD on day 0 and etoposide (8 mg/kg) on days 0, 1, and 2; LCNEC: cisplatin (5 mg/kg) SD. AJCC, American Joint Committee on Cancer.

Tumor typePDXAJCC
stage
Untreated TIC
frequency*
SOCDLL3
protein
(ng/mg)
SC16LD6.5
%TGI
(dTTP;
days)
Dose level
(mg/kg)
Regimen%TGI
(dTTP;
days)
SCLCLU64IV1:18986 (18)4.251Q4D×3100 (133)
LU73IIIa1:13686 (28)2.771Q4D×377 (32)
LU80IV1:14382 (14)0.601Q4D×355 (4)
LU86IV1:3139 (0)3.051Q4D×380 (32)
LU95IV1:6056 (14)6.521Q4D×395 (115)
LU100Ia1:166100 (64)0.0011Q4D×396 (3)
LU117IV1:38899 (25)2.951Q4D×399 (137)
LU124IIIb1:27185 (14)3.231Q4D×372 (35)
LU129IVN.D.84 (32)N.D.1Q4D×395 (106)
LU149IV1:20793 (21)2.711Q4D×399 (142)
Mean81 (23)87 (74)
SEM6 (5)5 (18)
Median86 (17)95 (71)
LCNECLU37IIb1:1660 (4)5.191Q4D×397 (132)
LU240IIb1:3127 (0)28.572SD95 (42)
Mean44 (2)96 (87)
SEM17 (2)1 (45)
Median44 (2)96 (87)

*Determined by implanting various cell doses (2 to 1000 cells) of dissociated cells from passage 2 to 5 PDX into mice.

†IgG1.LD6.5 data not available; dTTP value represents TTP.